Properties
- Form
- liofilizati saineqcio khsnaris mosamzadeblad
- Dosage mg
- 8
- Pack
- 3
What is it?
International Nonproprietary Name - Lornoxicamum Composition 1 vial contains: Active substance: 8 mg Lornoxicam. Excipients: Mannitol, Trometamol, Disodium Edetate Solvent: Water for injection – 2 ml. Pharmacotherapeutic group Non-steroidal anti-inflammatory drugs. Oxicams. Indications Short-term therapy of acute pain of mild to moderate intensity. Dosage and administration The injection solution is prepared immediately before use by dissolving the contents of one vial (8 mg Lornoxicam powder) in water for injection (2 ml). After preparing the solution, the needle is changed. Intramuscular injection is administered with a long needle. The duration of intravenous administration of the solution should be at least 15 seconds, and intramuscular administration - at least 5 seconds. For postoperative pain, the prepared solution is administered intravenously or intramuscularly, and for acute lumbago/sciatica attacks, intramuscularly. The initial dose may be 8 or 16 mg. If the analgesic effect is insufficient, an additional dose of 8 mg may be administered. Maintenance therapy: 8 mg 2 times a day. The maximum daily dose should not exceed 16 mg. It is recommended to use the minimum effective dose for the shortest possible duration. Contraindications - Hypersensitivity/allergy to Lornoxicam or any of the drug's components; - History of bronchial asthma, recurrent nasal polyposis fully or partially developed in connection with the intake of acetylsalicylic acid or other NSAIDs, as well as their intolerance; - Hemorrhagic diathesis or blood coagulation disorders, as well as previous surgeries with a risk of concomitant bleeding or incomplete hemostasis; - Post-coronary artery bypass grafting period; - Cerebrovascular hemorrhage; - Erosive-ulcerative changes of the gastric and duodenal mucosa, active gastrointestinal bleeding; - Recurrent gastric ulcer or recurrent gastrointestinal bleeding; - History of gastrointestinal bleeding associated with NSAID use; - Inflammatory bowel diseases (Crohn's disease, non-specific ulcerative colitis) in the exacerbation phase; - Decompensated heart failure; - Severe hepatic insufficiency or active liver disease; - Severe renal insufficiency (serum creatinine level >300 µmol/L); - Confirmed hypercalcemia, hypovolemia or dehydration; - Pregnancy and lactation period; - Children and adolescents under 18 years of age (due to lack of clinical data in this age group); Side effects Side effects are classified according to their frequency of occurrence as follows: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10,000, <1/1000); very rare (<1/10,000), frequency not known (frequency cannot be estimated from available data). Infections: Rare – pharyngitis. Blood and lymphatic system disorders: Rare – anemia, thrombocytopenia, leukopenia, prolonged bleeding time; very rare – ecchymosis. NSAIDs can cause potentially severe hematological disorders such as: neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia. Immune system disorders: Rare – hypersensitivity reactions, anaphylactic reaction and anaphylactic shock. Metabolism and nutrition disorders: Uncommon – decreased appetite, changes in body weight. Psychiatric disorders: Uncommon – insomnia, depression; Rare – nervousness, feeling of detachment, agitation. Nervous system disorders: Common – mild, transient headache, dizziness; Rare – somnolence, paresthesia, dysgeusia, tremor, migraine; very rare – aseptic meningitis in patients with systemic lupus erythematosus and mixed connective tissue disease.
